Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Miswiring the brain: Δ9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway.

Tortoriello G, Morris CV, Alpar A, Fuzik J, Shirran SL, Calvigioni D, Keimpema E, Botting CH, Reinecke K, Herdegen T, Courtney M, Hurd YL, Harkany T.

EMBO J. 2014 Apr 1;33(7):668-85. doi: 10.1002/embj.201386035. Epub 2014 Jan 27.

2.

Fetal cannabinoid receptors and the "dis-joint-ed" brain.

Cristino L, Di Marzo V.

EMBO J. 2014 Apr 1;33(7):665-7. doi: 10.1002/embj.201488086. Epub 2014 Mar 14.

3.

Delta9-tetrahydrocannabinol is a full agonist at CB1 receptors on GABA neuron axon terminals in the hippocampus.

Laaris N, Good CH, Lupica CR.

Neuropharmacology. 2010 Jul-Aug;59(1-2):121-7. doi: 10.1016/j.neuropharm.2010.04.013. Epub 2010 Apr 22.

4.

Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons.

de Salas-Quiroga A, Díaz-Alonso J, García-Rincón D, Remmers F, Vega D, Gómez-Cañas M, Lutz B, Guzmán M, Galve-Roperh I.

Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13693-8. doi: 10.1073/pnas.1514962112. Epub 2015 Oct 12.

5.

Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects.

Ellgren M, Artmann A, Tkalych O, Gupta A, Hansen HS, Hansen SH, Devi LA, Hurd YL.

Eur Neuropsychopharmacol. 2008 Nov;18(11):826-34. doi: 10.1016/j.euroneuro.2008.06.009.

6.

Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.

Lombard C, Hegde VL, Nagarkatti M, Nagarkatti PS.

J Pharmacol Exp Ther. 2011 Nov;339(2):607-17. doi: 10.1124/jpet.111.181206. Epub 2011 Aug 10.

7.

A comparison of the apoptotic effect of Delta(9)-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex.

Downer EJ, Gowran A, Campbell VA.

Brain Res. 2007 Oct 17;1175:39-47. Epub 2007 Aug 16.

PMID:
17884022
8.

Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memory.

Sousa VC, Assaife-Lopes N, Ribeiro JA, Pratt JA, Brett RR, Sebastião AM.

Neuropsychopharmacology. 2011 Jan;36(2):472-87. doi: 10.1038/npp.2010.179. Epub 2010 Oct 6.

9.

Sex-specific alterations in hippocampal cannabinoid 1 receptor expression following adolescent delta-9-tetrahydrocannabinol treatment in the rat.

Silva L, Harte-Hargrove L, Izenwasser S, Frank A, Wade D, Dow-Edwards D.

Neurosci Lett. 2015 Aug 18;602:89-94. doi: 10.1016/j.neulet.2015.06.033. Epub 2015 Jun 26.

10.

Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice.

Morgan DJ, Davis BJ, Kearn CS, Marcus D, Cook AJ, Wager-Miller J, Straiker A, Myoga MH, Karduck J, Leishman E, Sim-Selley LJ, Czyzyk TA, Bradshaw HB, Selley DE, Mackie K.

J Neurosci. 2014 Apr 9;34(15):5152-63. doi: 10.1523/JNEUROSCI.3445-12.2014.

11.

Δ9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling.

Chen R, Zhang J, Fan N, Teng ZQ, Wu Y, Yang H, Tang YP, Sun H, Song Y, Chen C.

Cell. 2013 Nov 21;155(5):1154-65. doi: 10.1016/j.cell.2013.10.042. Erratum in: Cell. 2014 Jan 30;156(3):618.

12.

Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.

Romero J, Garcia-Palomero E, Castro JG, Garcia-Gil L, Ramos JA, Fernandez-Ruiz JJ.

Brain Res Mol Brain Res. 1997 Jun;46(1-2):100-8.

PMID:
9191083
13.

Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice.

Monory K, Blaudzun H, Massa F, Kaiser N, Lemberger T, Schütz G, Wotjak CT, Lutz B, Marsicano G.

PLoS Biol. 2007 Oct;5(10):e269.

14.

Δ9-tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB 2, disrupting early activation events.

Karmaus PW, Chen W, Kaplan BL, Kaminski NE.

J Neuroimmune Pharmacol. 2012 Dec;7(4):843-55. doi: 10.1007/s11481-011-9293-4. Epub 2011 Jul 26.

15.

Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors.

Viñals X, Moreno E, Lanfumey L, Cordomí A, Pastor A, de La Torre R, Gasperini P, Navarro G, Howell LA, Pardo L, Lluís C, Canela EI, McCormick PJ, Maldonado R, Robledo P.

PLoS Biol. 2015 Jul 9;13(7):e1002194. doi: 10.1371/journal.pbio.1002194. eCollection 2015 Jul 9.

16.

Synaptic targets of Δ9-tetrahydrocannabinol in the central nervous system.

Hoffman AF, Lupica CR.

Cold Spring Harb Perspect Med. 2013 Aug 1;3(8). pii: a012237. doi: 10.1101/cshperspect.a012237. Review.

17.

Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.

Springs AE, Karmaus PW, Crawford RB, Kaplan BL, Kaminski NE.

J Leukoc Biol. 2008 Dec;84(6):1574-84. doi: 10.1189/jlb.0508282. Epub 2008 Sep 12.

18.

The tumour suppressor protein, p53, is involved in the activation of the apoptotic cascade by Delta9-tetrahydrocannabinol in cultured cortical neurons.

Downer EJ, Gowran A, Murphy AC, Campbell VA.

Eur J Pharmacol. 2007 Jun 14;564(1-3):57-65. Epub 2007 Feb 22.

PMID:
17379209
20.

SCG10 is a JNK target in the axonal degeneration pathway.

Shin JE, Miller BR, Babetto E, Cho Y, Sasaki Y, Qayum S, Russler EV, Cavalli V, Milbrandt J, DiAntonio A.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):E3696-705. doi: 10.1073/pnas.1216204109. Epub 2012 Nov 27.

Supplemental Content

Support Center